Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Category: #health  By Saipriya Iyer  Date: 2019-11-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac failure.

The results were presented on November 7, 2019, at the American Heart Association Annual Meeting. Triple Gene is owned is a majorly owned subsidiary of Intrexon Corporation.

According to Thomas D. Reed, Co-founder and Managing Director at Triple Gene, the data proposes that the combination of the company’s newly developed non-integrating naked plasmid DNA with focused cardiac delivery supported by Retrograde Coronary Sinus Infusion carries the ability to open a new biologics treatment model. It could be used for the treatment of cardiovascular diseases, he further added.

Triple Gene’s Co-founder and Clinical Director, Amit N. Patel, MD, MS, was reportedly quoted stating that 12 patients in the clinical trial have received the drug dosage between the two clinical sites at the University of Arizona, Tucson and The Christ Hospital, Cincinnati. Presently, the company is exploring clinical study designs that consider repetitive dosing along with additional orphan-like heart failure subtypes.

For the record, the investigational therapy by Triple Gene utilizes the non-viral delivery mechanism of a controlled multigenic plasmid developed to express human S100A1, VEGF165 and SDF-1a gene products that may affect progenitor cell recruitment, calcium handling, and angiogenesis. It also targets the fundamental  mechanisms associated with pathological myocardial remodeling. Further, the plasmid treatment is rendered through RCSI, which facilitates cardiac-specific delivery to the heart’s ventricle.

About Triple-Gene

Triple Gene primarily focuses on developing controllable, targeted and multigenic gene therapies to diagnose cardiovascular diseases. The company’s main product is a non-viral clinical gene therapy candidate that drives expression of three candidate genes which are effectively associated with heart failure. 

 

 

Source Credits: https://3gtx.com/wp-content/uploads/2019/11/Triple-Gene_Presented_Preliminary_Phase_1_Trial_Data_at_AHA_Annual_Meeting.pdf



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...

Regeneron begins late-stage trial of its coronavirus antibody cocktail
Regeneron begins late-stage trial of its coronavirus antibody cocktail
By Saipriya Iyer

Renowned American biopharmaceutical company, Regeneron Pharmaceuticals, has reportedly announced that it has started late-stage clinical trials of its proprietary antibody cocktail to assess its effectiveness in treati...